Belite Bio

About Belite Bio

Belite Bio (NASDAQ: BLTE) is a clinical-stage biopharmaceutical company, incorporated in 2018 and headquartered in San Diego, California, concentrating on developing treatments for retinal degenerative diseases with significant unmet medical needs. The company's origins trace back to its founder, Dr. Tom (Yu-Hsin) Lin, who identified a promising drug candidate while pursuing his MBA at Columbia Business School. Dr. Lin, who serves as Chairman and CEO, holds a PhD in Medicine from the University of Sydney and founded Lin BioScience, which remains Belite Bio's controlling shareholder. Belite was established to advance this candidate, with Dr. Lin making a successful business case to Columbia University to acquire the rights.

The company's business is centered on its lead product candidate, Tinlarebant (also known as LBS-008), an oral, once-a-day tablet. This therapy is designed to treat Stargardt disease type 1 (STGD1), the most common inherited macular dystrophy causing vision loss in children and adolescents, and Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). Currently, there are no approved treatments for STGD1 and no approved oral therapies for GA. The company's revenue model will depend on the successful commercialization of Tinlarebant upon regulatory approval. The potential market is substantial, as GA affects millions globally, while STGD1 is a rare disease affecting a smaller patient population.

Tinlarebant functions as a retinol-binding protein 4 (RBP4) antagonist. Its mechanism involves reducing the levels of RBP4, the sole carrier protein that transports vitamin A (retinol) from the liver to the eye. By modulating retinol delivery, Tinlarebant aims to decrease the accumulation of toxic vitamin A by-products (bisretinoids) in the retina, which are a key cause of retinal cell death in both STGD1 and GA. This approach spares patients from invasive eye injections, a common delivery method for other retinal therapies.

The company is advancing Tinlarebant through late-stage clinical trials. The Phase 3 DRAGON trial for STGD1 has completed enrollment and is expected to report topline results in late 2025, with plans to submit for regulatory approval in the first half of 2026. The pivotal Phase 3 PHOENIX trial for GA has also completed enrollment of 500 subjects. Tinlarebant has received multiple favorable regulatory designations for STGD1, including Fast Track, Rare Pediatric Disease, and Breakthrough Therapy in the US, as well as Orphan Drug designation in the US, Europe, and Japan.